Namrata S. Patil

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study

Byoung Chul Cho, Delvys Rodríguez‐Abreu, Maen Hussein et al. · The Lancet Oncology · 2022 · 424 citations · Full text

Medicine, Oncology, Pharmacology +14

Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer

Namrata S. Patil, Barzin Y. Nabet, Sören Müller et al. · Cancer Cell · 2022 · 403 citations

Medicine, Immunology, Oncology +16

Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).

Delvys Rodríguez‐Abreu, Melissa L. Johnson, Maen Hussein et al. · Journal of Clinical Oncology · 2020 · 242 citations

Medicine, Oncology, Pharmacology +17

NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes

Anju Singh, Anneleen Daemen, Dorothee Nickles et al. · Clinical Cancer Research · 2020 · 174 citations · Full text

Medicine, Cancer Biology, Oncology +17

Molecular determinants of response to PD-L1 blockade across tumor types

Romain Banchereau, Ning Leng, Oliver A. Zill et al. · Nature Communications · 2021 · 171 citations · Full text

Medicine, Cancer Biology, Oncology +17